Impact of 2+1 pneumococcal conjugate vaccine program in the province of Quebec, Canada

Vaccine

Volumn 32, Issue 13, 2014, Pages 1501-1506

  De Wals, Philippe ^a,b,c   Lefebvre, Brigitte ^b   Markowski, France ^d   Deceuninck, Geneviève ^c   Defay, Fannie ^c   Douville Fradet, Monique ^b   Landry, Monique ^d  

^a UNIVERSITÉ LAVAL   (Canada)

^b INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

^c LAVAL UNIVERSITY   (Canada)

^d MINISTRY OF HEALTH   (Canada)

Author keywords

Effectiveness; Herd immunity; Immunization program; Pneumococcal conjugate vaccine; Replacement

Indexed keywords

PNEUMOCOCCUS VACCINE;

ARTICLE; CANADA; CHILD; DRUG EFFICACY; FEMALE; HEALTH PROGRAM; HERD IMMUNITY; HUMAN; IMMUNIZATION; INCIDENCE; INFANT; MAJOR CLINICAL STUDY; MALE; NEWBORN; PNEUMOCOCCAL INFECTION; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SEROTYPE;

EFFECTIVENESS; HERD IMMUNITY; IMMUNIZATION PROGRAM; PNEUMOCOCCAL CONJUGATE VACCINE; REPLACEMENT;

ADULT; AGED; AGED, 80 AND OVER; CHILD, PRESCHOOL; DISEASE NOTIFICATION; HUMANS; IMMUNIZATION PROGRAMS; IMMUNIZATION SCHEDULE; INCIDENCE; INFANT; INFANT, NEWBORN; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; QUEBEC; REGISTRIES; SEROTYPING; STREPTOCOCCUS PNEUMONIAE; VACCINES, CONJUGATE; YOUNG ADULT;

EID: 84896696932     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.11.028     Document Type: Article

References (26)

1. Butler J.C. Epidemiology of pneumococcal disease. The pneumococcus 2004, 136-147. ASM Press, Washington, DC. E.I. Tuomanen, T.J. Mitchell, D.A. Morrison, B.G. Spratt (Eds.).
2. National Advisory Committee on Immunization (NACI) Statement on recommended use of pneumococcal conjugate vaccine. CCDR 2002, 28(ACS-2):1-32.
3. De Wals P. Optimizing the acceptability, effectiveness and costs of immunization programs: the Quebec experience. Expert Rev Vaccines 2011, 10:55-62.
4. Quebec Immunization Committee Assessment of the appropriateness of an immunization program for pneumococcal infections in children using a reduced number of doses of conjugate vaccine 2005, Institut national de santé publique du Québec, Montreal, QC, Available at: .
5. De Wals P., Boulianne N., Sévin É., Ouakki M., Deceuninck G., Guay M. Uptake of pneumococcal conjugate vaccine: methodological issues in measurement and impact of publicly funded programs. Can J Public Health 2009, 100:413-416.
6. Boulianne N., Bradet R., Audet D., Ouakki M. Enquête sur la couverture vaccinale des enfants de 1 an et 2 ans au Québec en 2010 2011, Institut national de santé publique du Québec, Quebec City, QC, Available at: .
7. Comité sur l'immunisation du Québec (CIQ) Évaluation de la pertinence d'un nouveau vaccin antipneumococcique conjugué au Québec 2009, Institut national de santé publique du Québec, Quebec City, QC, Available at: .
8. Comité sur l'immunisation du Québec (CIQ) Évaluation de deux nouveaux vaccins pneumococciques conjugués pour l'immunisation des enfants au Québec 2010, Institut national de santé publique du Québec, Quebec City, QC, Available at: .
9. Myint T.T.H., Madhava H., Balmer P., Christopoulou D., Attal S., Menegas D., et al. The impact of 7-valent pneumococcal conjugate vaccine on invasive pneumococcal disease: a literature review. Adv Ther 2013, 10.1007/s12325-013-0007-6.
10. De Wals P., Lefebvre B., Defay F., Deceuninck G., Boulianne N. Invasive pneumococcal diseases in birth cohorts vaccinated with PCV-7 and/or PHiD-CV in the province of Quebec, Canada. Vaccine 2012, 30:6416-6420.
11. Miller E., Andrews N.J., Waight P.A., Slack M.P.E., George R.C. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis 2011, 11:760-768.
12. Harboe Z.B., Valentiner-Branth P., Ingels H., Rasmussen J.N., Andersen P.H.S., Bjerre C.C., et al. Pediatric invasive pneumococcal disease caused by vaccine serotypes following the introduction of conjugate vaccination in Denmark. PLoS One 2013, 8:e51460. 10.1371/journal.pone.0051460.
13. Pilishvili T., Lexau C., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010, 201:32-41.
14. Leal J., Vanderkooi O.G., Church D.L., MacDonald J., Tyrrell G.J., Kellner J.D. Eradication of invasive pneumococcal disease due to the seven-valent pneumococcal conjugate vaccine serotypes in Calgary, Alberta. Pediatr Infect Dis J 2012, 31:e169-e175.
15. Palmu A.A., Jokinen J., Borys D., Nieminen H., Ruokokoski E., Siira L., et al. Effectiveness of the ten-valent pneumococcal Haemophilus influenza protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial. Lancet 2013, 381:214-222.
16. Pelton S.I., Weycker D., Klein J.O., Strutton D., Ciuryla V., Oster G. 7-Valent pneumococcal conjugate vaccine and lower respiratory tract infections: effectiveness of a 2-dose versus 3-dose primary series. Vaccine 2010, 28:1575-1582.
17. Stoecker C., Hampton L.M., Moore M.R. 7-Valent pneumococcal conjugate vaccine and otitis media: effectiveness of a 2-dose versus 3-dose primary series. Vaccine 2012, 30:6256-6262.
18. Beutels P., Thiry N., Van Damme P. Convincing or confusing? Economic evaluations of childhood pneumococcal conjugate vaccination-a review (2002-2006). Vaccine 2007, 25:1355-1367.
19. Public Health Agency of Canada Publicly funded immunization programs in Canada. Routine schedule for infants and children including special programs and catch-up programs (as of December 2012) 2013, Public Health Agency of Canada, Ottawa, ON, Available at: .
20. Weinberger D.M., Malley R., Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. Lancet 2011, 378:1962-1973.
21. Statistics Canada. The Daily Child care: an eight-year profile 1994-1995 to 2002-2003. Available at: .
22. Singleton R.J., Hennessy T.W., Bulkow L.R., Hammitt L.L., Zulzt T., Hurlburt D.A., et al. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska Native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. J Am Med Assoc 2007, 297:1784-1792.
23. Prymula R., Schuerman L. 10-Valent pneumococcal nontypeable Haemophilus influenzae PD conjugate vaccine: Synflorix™. Expert Rev Vaccines 2009, 8:1479-1500.
24. Kaplan S.L., Barson W.J., Lin P.L., Romero J.R., Bradley J.S., Tan T.Q., et al. Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2013, 32:203-207.
25. Deceuninck G., De Wals P., Boulianne N., De Serres G. Effectiveness of pneumococcal conjugate vaccine using a 2+1 infant schedule in Quebec, Canada. Pediatr Infect Dis J 2010, 29:546-549.
26. Douville-Fradet M., Amini R., Boulianne N., Khuc N.H., De Wals P., Fortin É., et al. Impact du programme d'immunisation par le vaccin pneumococcique conjugué heptavalent (VPC-7) au Québec 2011, Institut national de santé publique du Québec, Quebec City, QC, Available at: .